The factors of residual tumor grade and histologic regression grade also had good correlations with the prognosis (residual tumor grade, P =.0324; histologic regression grade, P <.0001).
Tumor regression rate, residual tumor grade, and histologic regression grade to the preoperative therapy were analyzed to determine their influence on the prognosis.
Conclusions: The findings of the present study suggest that response to preoperative chemoradiotherapy, such as tumor regression rate, residual tumor grade, and histologic regression grade, could be of prognostic value in patients with tongue carcinoma.
The following system of tumour regression was used: grade 1, complete (0% residual tumour); grade 2, subtotal and partial tumour regression (1 50% residual tumour per tumour bed); and grade 3, minimal or no tumour regression (>50% residual tumour per tumour bed).
The aim of this study was to determine the objective response rate and response duration of hormonal treatment for recurrent or residual low-grade ESS in a consecutive series of patients.
For response (pCR vs. residual disease), grade was the only clinical covariate significantly associated with response.
Final pathologic examination revealed residual high-grade DCIS with necrosis (2.7 cm); however no residual invasive carcinoma was identified.
Patients who do not strictly meet these criteria but for whom further treatment with oxaliplatin would be prohibited (for instance, allergic reaction, residual neurotoxicity grade ≥2) are allowed for inclusion.
Initial therapy consisted of 7 cycles of intensively dosed vincristine with doxorubicin and cyclophosphamide (cycles 1-3 and 7) and ifosfamide plus etoposide given over 6 months; scapulectomy after cycle 3 revealed predominantly viable residual tumor (grade I necrosis).
The occurrence of disease progression during third-line therapy defines the end of treatment strategy in arm B. If the patient remains eligible for reintroduction of an oxaliplatin-based chemotherapy (i.e., no prior progression during FOLFOX or XELOX and residual neuropathy grade ≤ 2), the end of treatment strategy is defined at the date of progression after this reintroduction.
